Rxo (RXO) Common Equity (2021 - 2026)

Rxo (RXO) has reported Common Equity for 6 consecutive years, with $1.5 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 5.16% year-over-year to $1.5 billion; the trailing twelve-month figure through Jun 2026 stood at $1.5 billion (down 5.16% YoY), and the FY2025 full-year result was $1.5 billion, down 4.4% from the prior year.
• Common Equity was little changed at $1.5 billion in Q2 2026 per RXO's latest filing, from $1.5 billion in the prior quarter.
• Across five years, Common Equity topped out at $1.7 billion in Q3 2024 and bottomed at $579.0 million in Q2 2024.
• Historically, Common Equity has averaged $1.1 billion across 5 years, with a median of $1.2 billion in 2022.
• The sharpest annual moves came in 2023 and 2024: Common Equity slumped 50.88% in 2023, then soared 180.0% in 2024.
• Over 5 years, Common Equity stood at $587.0 million in 2022, then increased by 1.19% to $594.0 million in 2023, then jumped by 171.38% to $1.6 billion in 2024, then declined by 4.4% to $1.5 billion in 2025, then retreated by 2.27% to $1.5 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $1.5 billion, $1.5 billion, and $1.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.